Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025
– New findings demonstrate a 72% HI-E response rate at Week 16…
TACC Positions India as a Global Hub for Advanced Energy Materials
Leveraging HEG's global legacy, the company aims to build a cost-competitive and…
Rathbones calls for urgent regional investment to drive UK growth
One of UK's leading wealth managers, with offices and clients across the…
World Psoriasis Day 2025: IFPA Calls to Stop the Domino Effect of Psoriasis
IFPA urges recognition of the close link between psoriasis and mental health…
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving…
EyePoint Announces Proposed Public Offering of Common Stock
October 14, 2025 16:35 ET Â | Source: EyePoint Pharmaceuticals, Inc. WATERTOWN, Mass.,…
AV-Comparatives Nominated for Euregio Innovation Award at European Forum Alpbach 2025
Research uncovers serious vulnerabilities across multiple devices from two major smart home…
MG 3 receives four stars but suffers rare and serious seat failure in Euro NCAP crash test
LEUVEN, BELGIUM – For decades, MG’s catchy slogan was ‘Safety Fast’ as…
Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism
September 06, 2025 14:30 ET Â | Source: BridgeBio Pharma, Inc. - 80%…
Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information…